Literature DB >> 15887291

High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.

Sietske A Riemersma1, Joost J Oudejans, Marcel J Vonk, Enno J Dreef, Frans A Prins, Patty M Jansen, Maarten H Vermeer, Paul Blok, Robbie E Kibbelaar, Jettie J F Muris, Ed M D Schuuring, Philip M Kluin.   

Abstract

Loss of both HLA class I and class II expression in B cell lymphomas is a mechanism of escape from a cytotoxic T lymphocyte (CTL) immune response and will therefore give a strong selective survival advantage in tumours expressing strong immunogenic antigens. We investigated loss of HLA expression using specific antibodies on tissue sections from 254 B cell lymphomas originating from nodal and different extranodal sites in relation to numbers of tumour-infiltrating T cells. Complete loss of HLA class I and II was observed in a minority of the nodal, stomach, and skin lymphomas but in the majority of the lymphomas originating from the testis and the CNS. Interestingly, relatively high percentages of activated CTLs were detected in both primary testicular and CNS lymphomas compared to lymphomas at other sites, with highest percentages in the testis (p < 0.0001). We conclude that loss of both HLA class I and II expression occurs very frequently in lymphomas originating from the testis and the CNS as compared to nodal and some other extranodal sites. The presence of high percentages of activated CTLs in the testicular and CNS lymphomas suggests that loss of HLA expression provides a strong growth advantage for lymphoma cells in these immune-privileged sites. Copyright 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887291     DOI: 10.1002/path.1783

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas.

Authors:  Kohei Fukuoka; Yasin Mamatjan; Ruth Tatevossian; Michal Zapotocky; Scott Ryall; Ana Guerreiro Stucklin; Julie Bennett; Liana Figueiredo Nobre; Anthony Arnoldo; Betty Luu; Ji Wen; Kaicen Zhu; Alberto Leon; Dax Torti; Trevor J Pugh; Lili-Naz Hazrati; Normand Laperriere; James Drake; James T Rutka; Peter Dirks; Abhaya V Kulkarni; Michael D Taylor; Ute Bartels; Annie Huang; Gelareh Zadeh; Kenneth Aldape; Vijay Ramaswamy; Eric Bouffet; Matija Snuderl; David Ellison; Cynthia Hawkins; Uri Tabori
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

Review 2.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

Review 3.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

4.  Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers.

Authors:  Noriko Tonomura; Ingegerd Elvers; Rachael Thomas; Kate Megquier; Jason Turner-Maier; Cedric Howald; Aaron L Sarver; Ross Swofford; Aric M Frantz; Daisuke Ito; Evan Mauceli; Maja Arendt; Hyun Ji Noh; Michele Koltookian; Tara Biagi; Sarah Fryc; Christina Williams; Anne C Avery; Jong-Hyuk Kim; Lisa Barber; Kristine Burgess; Eric S Lander; Elinor K Karlsson; Chieko Azuma; Jaime F Modiano; Matthew Breen; Kerstin Lindblad-Toh
Journal:  PLoS Genet       Date:  2015-02-02       Impact factor: 5.917

5.  Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.

Authors:  Rui Wu; Marcel Nijland; Bea Rutgers; Rianne Veenstra; Myra Langendonk; Lotte E van der Meeren; Philip M Kluin; Guanwu Li; Arjan Diepstra; Jen-Fu Chiu; Anke van den Berg; Lydia Visser
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

6.  HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Authors:  Marcel Nijland; Rianne N Veenstra; Lydia Visser; Chuanhui Xu; Kushi Kushekhar; Gustaaf W van Imhoff; Philip M Kluin; Anke van den Berg; Arjan Diepstra
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

7.  T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.

Authors:  Suvi-Katri Leivonen; Marjukka Pollari; Oscar Brück; Teijo Pellinen; Matias Autio; Marja-Liisa Karjalainen-Lindsberg; Susanna Mannisto; Pirkko-Liisa Kellokumpu-Lehtinen; Olli Kallioniemi; Satu Mustjoki; Sirpa Leppä
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

8.  Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

Authors:  Claire Galand; Sabrina Donnou; Thierry Jo Molina; Wolf Herman Fridman; Sylvain Fisson; Catherine Sautès-Fridman
Journal:  Front Immunol       Date:  2012-05-04       Impact factor: 7.561

9.  Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.

Authors:  Valentin P Shichkin; Roman M Moriev
Journal:  ScientificWorldJournal       Date:  2014-02-16

Review 10.  Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.

Authors:  John Apostolidis; Ayman Sayyed; Mohammed Darweesh; Panayotis Kaloyannidis; Hani Al Hashmi
Journal:  J Immunol Res       Date:  2020-10-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.